Ebstein’s Anomaly Market Report 2023: R&D Consistency Drives Sector GrowthPosted by Ganesh Shinde on February 23rd, 2023 During the forecast period 2023 to 2033, the Ebstein’s anomaly market is expected to grow at a value of 8% CAGR, according to Future Market Insights. By the year 2033, the global market for Ebstein’s anomaly is expected to rise up to a market valuation of US$ 30 Billion. The growing prevalence of Ebstein’s anomaly in babies is expected to drive the growth of the market. During the COVID-19 pandemic, the treatment for Ebstien’s anomaly observed a downfall owing to the disruption in supply chain management across the globe. Moreover, there was a slump in the research and development activities owing to the lack of funds caused by COVID-19 pandemic. In the upcoming forecast period, the use of technologically advanced healthcare related machines is expected to offer different medications and treatment for the ailment. Furthermore, North America and Asia Pacific are two major regions contributing to the growth of the Ebstein’s market. This is owing to various government initiatives along with presence of advanced treatments in the region. A growing inclination towards hospitals has been observed due to the availability of varied nature of diagnosis and treatments. The amalgamation of technology and extensive research is expected to benefit the market in the upcoming years. Competitive Landscape Some of the key players in Ebstein’s Anomaly market are Abbott Vascular, Boston Scientific Corporation, Cordis Corporation, Edwards Lifesciences, GE Healthcare, Gore Medical, Medtronic, Inc. and Numed, Inc among others. Read More@ https://www.futuremarketinsights.com/reports/ebsteins-anomaly-market Key Segments Profiled in the Ebstein’s Anomaly Industry Survey Treatment:
Diagnosis:
End User:
Like it? Share it!More by this author |